UBS analyst Joshua Spector lowered the firm’s price target on Cabot (CBT) to $74 from $75 and keeps a Neutral rating on the shares. UBS is not modeling a major change in the macro in 2026, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBT:
- Cabot price target raised to $81 from $79 at Jefferies
- Cabot signs multi-year supply agreement with PowerCo SE
- Cabot price target raised to $80 from $72 at Mizuho
- Cabot price target lowered to $54 from $75 at JPMorgan
- Cabot Corp’s AI Challenges: Navigating Risks and Competitive Pressures